Abstracts accepted for a poster presentation!
- Clinical characteristics of Australian treatment-naïve classical Hodgkin Lymphoma (cHL) patients from the Lymphoma and Related Diseases Registry (LaRDR)
- Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian cohort: an analysis of the Lymphoma and Related Diseases Registry
- Ibrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL): interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry
- Ibrutinib in relapsed/refractory chronic lymphocytic leukaemia: interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry
- Real world management of Lymphoma and Related diseases in Australia: The first five years of the Lymphoma and Related Diseases Registry (LaRDR)
The Blood 2021 Meeting is scheduled for September 20 – 23, 2021 in Adelaide Convention Centre. More information about the presentation will be provided.
Stay tuned for Breakfast Meeting!
The breakfast meeting is co-organised by ALA and LaRDR .
Stay tuned for more updates.
What is LaRDR?
The Lymphoma and Related Diseases Registry (LaRDR) is an Australasian initiative to improve the treatment and outcomes of patients with lymphoma.
The LaRDR is managed by Monash University’s School of Public Health and Preventive Medicine, through the Transfusion Research Unit, which manages a number of other clinical registries for important blood disorders.
The registry will include all new cases of Hodgkin and non-Hodgkin lymphomas at registered hospital sites. National representative data on diagnosis and treatment will be collected, allowing the LaRDR team to
- Understand access to care
- Monitor trends in practice, outcomes and survival
- Explore variation in factors that influence outcomes including survival and quality of life
- Benchmark outcomes nationally and internationally
- Act as a resource for clinical trials
Estimated number of new cases of Lymphoma diagnosed in Australia in 2019
Estimated number of deaths from Lymphoma in Australia in 2019
Chance of surviving Leukaemia in Australia for at least 5 years (2009-2013)